Greenwich LifeSciences Stock Gains on GP2 Update (GLSI)


Update the digital concept

Olemedia

Greenwich LifeSciences (NASDAQ:GLSI) rose on Wednesday after the immunotherapy developer updated on the commercial manufacture of its lead GP2 candidate, which is currently undergoing a late-stage trial called FLAMINGO-01 for breast cancer.

Given that commercial manufacturing data as well



Source link

  • Related Posts

    SK Hynix slumped after record profits fell short of high expectations

    Nvidia’s main supplier of high-bandwidth memory posted an operating profit of $5.6 billion in the December quarter, after a 75% increase in revenue. Read More Source link

    New wildfire near Los Angeles burns to 8,000 hectares, forcing evacuations By Reuters

    By David Swanson and Daniel Trotta CASTAIC, Calif. (Reuters) – A new wildfire that broke out north of Los Angeles on Wednesday quickly spread to more than 8,000 hectares (32…

    Leave a Reply

    Your email address will not be published. Required fields are marked *